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ABSTRACT
PURPOSE: Most successful treatment of the lung cancer patients is the surgical resection. Lung perfusion 
scintigraphy is established method in the complex pre-operative diagnostics of lung carcinoma. It is used 
for selection of candidates for surgical treatment and in determination of operability and in decision on the 
operation volume. 
MATERIALS AND METHODS: We analyzed retrospectively the value of lung perfusion scintigraphy in 27 
cases with primary lung carcinoma who had a lobectomy. Survival probability was calculated by Kaplan-
Meier method. The log rank test was used to compare survival rates between groups.
RESULTS: All patients with lobectomy were staged pre-operatively by noninvasive procedures at stages I-IIIA. 
The lung perfusion scintigraphy demonstrated an enlarged mediastinum at 1 of the patients. Impaired perfu-
sion in homolateral hilum and in the contralateral hilum was found in some of the patients. Changes in affect-
ed lung perfusion varied from impaired in different rate to perfusion defect. Perfusion indices at affected lung 
have mean=48,59%. The survival of patients with Perfusion index less than 49% was mean = 56,333 months, 
and median = 35 months (3 years). The survival of patients with Perfusion index more than 49% was mean = 
99,214 months, and median = 64 months (5.3 years). For I and II stage mean survival time was 120,727 months, 
and median survival time was 112 months (9.3 years). For IIIA and IIIB stage mean survival time was 48,667 
months, and median survival time was 29 months (2,4 years).
CONCLUSION: Lung perfusion scintigraphy is a valuable method in pre-operative diagnosis of lung carci-
noma in determination of the extent of perfusion impairment in the affected lung and for determination of 
functional operability. Lobectomy is possible when perfusion in affected lung is over 41%, but the lower per-
fusion is not surely a contraindication for lobectomy. The extent of perfusion impairment is proportional to 
survival rate. Patients with lower perfusion impairments have more than 5 years median survival. In post-
operative period perfusion scintigraphy shows re-distribution of perfusion in the healthy lung and in the 
rest of the operated lung. The survival of patients with lobectomy is corresponding to the clinical stage sta-
tistically significant.
Key words: lung carcinoma, lung perfusion scintigraphy, lobectomy
Received: December 12, 2013
Accepted: January 15, 2013
INTRoDUCTIoN
The carcinoma of the lung is the first cause for 
death worldwide. The most successful treatment of 
the patients is the surgical resection. The right selec-
tion of candidates for surgical treatment is of signif-
icant importance for the result and survival of the 
patients. Lung perfusion scintigraphy is established 
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method in complex pre-operative diagnostics of lung 
carcinoma. It has importance in determination of 
the extent of impairment of lung perfusion from the 
tumor process and in determination of operability 
and planning of the operative intervention volume. 
It is a valuable method together with inhalation scin-
tigraphy for determination of pulmonary function in 
patients with high risk for lung resection (6).
MATERIALS AND METHoDS
We analyzed retrospectively 27 consecutive 
cases with primary lung carcinoma treated in our 
departments. Every patient was subject to a stan-
dard postero-anterior and lateral chest x-ray, fiber-
optic bronchoscopy and to some of them chest CT 
and video-assisted thoracoscopy (VATS). There were 
25 men and 2 women. The age range was from 48 to 
69 years. The tumor was located in the right lung in 
12 patients and in the left lung in the remaining 14 
cases.
 Lung perfusion scintigraphy was performed in 
all patients with 99mTc- human albumin microspheres 
with a particle size of 23-45μm (kit Sferotec – Sorin 
Biomedica-Italy).The injection was applied in supine 
position, intravenously in bolus, 1ml at an activity of 
55-74MBq.The period of examination was between 
the 15th min and the 2nd hour after injection, at an-
terior, posterior, lateral and 45° detection, perfusion 
indices from 6 fields in front and posterior projec-
tion were calculated (Picker Dyna Camera 4 Scintil-
lation Camera System – Picker Corporation Nuclear 
and Ultrasound, USA).
We considered 4 pathological criteria for 
interpretation of lung perfusion scintigraphy:
1. Absent or minimal perfusion of the affected 
lung or a perfusion defect less than 1/3 of the 
affected lung.
2. Perfusion defect and enlargement of the hilum 
of the affected lung.
3. Enlargement and displacement of the 
mediastinum in anterior and/or posterior 
detection.
4. Perfusion defect in the contralateral hilum.
Lobectomy was performed at 27 patients. An 
invasive staging with mediastinoscopy before lobec-
tomy was not performed. The patients were staged in 
accordance with TNM classification (13).
Survival probability was calculated by Kaplan-
Meier method with the date of resection as a start-
ing point and included deaths from all cases with the 
presence of censored cases (for which the event has not 
occurred yet). The log rank test was used to compare 
survival rates between groups and Wilcoxon rank 
sum test was used to compare groups by stage and 
perfusion index (less 49% and higher than 49%). A P 
value of 0.05 was considered statistically significant.
RESULTS
All patients with lobectomy were staged pre-op-
eratively by noninvasive procedures at stages I-IIIA. 
The presence of NSCLC histology and performance 
status (Karnofsky index = 70-80). Four patients were 
with SCLC, which was diagnosed during the opera-
tion and on permanent histological preparation. The 
lung perfusion scintigraphy demonstrated an en-
larged mediastinum in front and posterior at 1 of the 
patients. Impaired perfusion in a zone with polycy-
clic outlines in homolateral hilum was present in 12 
of the patients, and in 2 – presented with only slightly 
impaired perfusion. Impaired perfusion in the con-
tralateral hilum was found in 2 of the patients, and in 
2 – slightly impaired. Changes in affected lung per-
fusion varied from impaired in different rate to per-
fusion defect. Impaired perfusion in only one seg-
ment and partially in second one was present in 7 of 
the patients. Impaired perfusion from slight to severe 
extent in not more than 3 segments was found in 11 
of the patients. Impaired perfusion in more than 3 
segments was present in 7 of the patients. Only one 
patient presented with perfusion defect in the whole 
lobe. No patient with perfusion defect involving less 
than 1/3 of the affected lung, a sign indicating unre-
sectability was found (16,17). Perfusion indices at lo-
calization in the right upper lobe (7 of the patients) 
were mean=50,15%, SD=4,7%, SE=2,4%. Perfusion 
indices at localization in the right lower lobe (4 of 
the patients) were mean=53,5%, SD=4,3%, SE=2,2%. 
Perfusion indices at localization in the right lung 
(11 of the patients) were mean=51,8%, SD=4,5%, 
SE=1,6%. Perfusion indices at localization in the 
left upper lobe (8 of the patients) were mean=43%, 
SD=5,8%, SE=2,6%. Perfusion indices at localiza-
tion in the left lower lobe (6 of the patients) were 
mean=49,15%, SD=11,2%, SE=5,6%. Perfusion indi-
ces at localization in the left lung (14 of the patients) 
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were mean=24,72%, SD=8,7%, SE=2,9%. Perfusion 
indices at affected lung, independently of right or left 
lung, were mean=48,59%, SD=7,5%, SE=1,8%.
On Fig. 1 is presented front and posterior pro-
jection of lung perfusion scintigraphy before opera-
tion of a man, 54 years of age with definitive diag-
nosis: Left lung carcinoma. Status after left upper lo-
bectomy with circular resection of left main bron-
chus and anastomosis with left lower lobe bronchus 
T2N1M0. After bronchoscopy is established full 
obliteration of left upper-lobe bronchus from blasto-
ma tissue with uneven surface and rose color. From 
perfusion scintigraphy severely impaired to lacking 
perfusion in the region of 1, 2 and 3 segments of left 
lung is found. Perfusion indices: right lung 68%, left 
lung 32%. Intra-operatively in the lumen of upper-
lobar bronchus a tumor is found, originating from 
short peduncle of 0,5 cm from the bifurcation of its 
lateral wall, with coral-like shape, occupying the lu-
men of upper-lobar bronchus as well as the lumens 
of segment bronchi, without sprouting in region-
al structures and without macroscopic data for me-
tastases in hilar lymph nodes. Left upper lobectomy 
is performed with circular resection and anastomo-
sis between left main bronchus and lower-lobe bron-
chus. Permanent preparation histology: small-cell 
undifferentiated carcinoma with metastasis from pa-
ra-aortal lymph nodes.
Perfusion scintigraphy in 4 of the patients was 
performed in different term after the operation (from 
9 days to 2 years). In post-operative period it is of im-
portance to follow the perfusion of the preserved 
lung part, especially in case of anastomosis. 
Fig. 1. Perfusion scintigraphy in front and posterior pro-
jection before operation of male 54 years of age patient 
with definitive diagnosis: Left pulmonary carcinoma. Sta-
tus after left upper lobectomy with circular resection of 
left main bronchus and anastomosis with left lower lobar 
bronchus. T2n1M0
Fig. 2. Perfusion scintigraphy of the patient from Fig 1 on 
day 9 after operation
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On Fig. 2. is shown the lung perfusion in front 
and posterior projection of the same patient from 
Fig.1, 9 days after the operation. The functioning 
lobe after the anastomosis is seen. Perfusion indices: 
right lung - 81,8%, left lung – 18,2%.
In peripheral carcinoma the smallest size tumor 
which has influenced perfusion is 4 cm. On Fig. 3 – 
perfusion scintigraphy before operation in front and 
posterior projection of a man on 55 years of age with 
definitive diagnosis: Right lung carcinoma T2N0M0 
I clinical stage. Status after upper right lobectomia. 
Histological result: undifferentiated spinocellular 
carcinoma. From perfusion scintigraphy is visual-
ized a small round zone with slight to moderate im-
pairment of perfusion in the region of the border of 
segment 1 and predominantly in segment 2 laterally 
of right lung in posterior projection. Intra-operative-
ly a solid peripheral tumor is found in the right upper 
lobe – 4 cm in diameter. 
Upper left lobectomy was performed on 9 of 
the patients (33,3%), and in 1 case a circular resec-
tion of main bronchus and anastomosis of the lower 
lobe was performed. Lower left lobectomy was per-
formed on 6 of the patients (22,3%), and in 1of the 
cases a wedge resection of S3 was performed and on 
another segmentectomy of S6. Right upper lobecto-
my was performed on 7 of the patients (25,9%), in-
cluding 2 cases with additional wedge resection of 
S6. Right lower lobectomy was performed on 4 of the 
patients (14,8%). Right lower bilobectomy was per-
formed on one of the patients (3,7%). All patients had 
systemic lymph dissection of hilar and mediastinal 
lymph nodes. 
Follow up of survival was performed on 23 of 
the patients, for the rest 4 there were no data avail-
able. We established that 3 of the patients have sur-
vived until now more than 15 years (187 months), 
over 18 years (220 months) and over 19 years (236 
months). They were staged respectively as stage I 
(broncho-alveolar carcinoma), stage II (small cell 
carcinoma) and stage IIIA (squamous cell carcino-
ma). There is one patient with longest survival – 253 
months (21 years and 3 months). 
Survival probability was calculated by Kaplan-
Meier method with the date of resection as a start-
ing point. Overall mean survival time was 83,879 
months, with 95% CI (48,648; 119,091), SE= 17,970. 
Overall median survival time was 41 months (3,4 
years), with 95% CI (22,218; 58,782), SE= 9,583. 
This means that for a particular patient, the chanc-
es of living beyond 3,4 years are 50%. On Fig. 4 is the 
graph for the process of development of the event in 
dynamics where censored are survivors. For I and II 
stage mean survival time was 120,727 months, with 
95% CI (65,565; 175,890) SE=28,144 and median 
survival time was 112 months, with 95% CI (40,79; 
183,21), SE=36,332. For IIIA and IIIB stage mean sur-
vival time was 48,667 months, with 95% CI (15,267; 
82,066), SE=17,041 and median survival time was 29 
months, with 95% CI (18,816; 39,184) SE=9,583. The 
median survival of patients with stage I or II is 112 
months (9,3 years). This means that for a particu-
lar patient, the chances of living beyond 9,3 years are 
50%. The median survival of patients with stage IIIA 
Fig. 3. Perfusion scintigraphy before operation in front 
and posterior projection of male 55 years of age with de-
finitive diagnosis: right lung carcinoma. T2n0M0, i clini-
cal stage. Status after right upper lobectomy
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or IIIB is 29 months (2,4 years). This means that for 
a particular patient, the chances of living beyond 2,4 
years are 50%. Data for survival according to stages 
are statistically significant (P=0,019). On Fig. 5 is a 
graph for survival according to the stage where cen-
sored are the survivors. 
The survival of patients with Perfusion in-
dex less than 49% is mean = 56,333 months, 95% CI 
(17,386; 95,281), SE=19,871 and median = 35 months, 
95% CI (20,391; 49,609), SE=7,454. The survival of pa-
tients with Perfusion index more than 49% is mean = 
99,214 months, 95% CI (50,693; 147,735), SE=24,756 
and median = 64 months, 95% CI (19,998; 108,002), 
SE=22,450. The median survival of patients with 
Perfusion index less than 49% is 35 months (3 years).
This means that for a particular patient, the chances 
of living beyond 3 years are 50%. The median surviv-
al of patients with Perfusion index more than 49% is 
64 monts (5.3 years). This means that for a particu-
lar patient, the chances of living beyond 5.3 years are 
50%. Data for survival in relation to Perfusion index 
are not statistically significant (P=0,263). 
On Fig. 6 is presented the graph of survival and 
relation to Perfusion index, where censored are the 
survivors. 
DISCUSSIoN
Levcheva V. et al. (11) in examination of pa-
tients with central bronchial carcinoma found de-
fects in perfusion adequate to hypo-ventilated zones, 
which gives the opportunity to predict the size of the 
planned pulmonary resection. They consider that di-
agnostic potential of perfusion lung scintigraphy ex-
clude or indicate additional invasive methods to di-
agnose pulmonary diseases.
Reduction of perfusion is expressed more than 
this of ventilation and to high extent in lobar and bi-
lobar cases, where in segment infiltration the values 
of both are in the normal range. For reduction of pul-
monary perfusion and ventilation, more important 
role has the parenchymal infiltration than bronchial 
obstruction (21).
Fig. 4. Survival of the patients after lobectomy indepen-
dently from the stage where censored are the survivors 
Fig. 5. Survival of the patients after lobectomy grouped 
by stages (i and ii stage) (iiiA and iiiB stage), where cen-
sored are the survivors
Fig. 6. Survival of the patients after lobectomy with Per-
fusion index less and more than 49%, where censored are 
the survivors
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The smallest peripheral tumor, which leads to 
perfusion changes in planar scan is with diameter 4 
cm (12), while with SPET a tumor over 3 cm is detect-
ed (15). We have found that peripheral tumor of 4 cm 
induces impaired perfusion.
If the perfusion in the affected lung is over 40%, 
lobectomy is always possible (17). Lobectomy is im-
possible in patients with perfusion less than 33% of 
the whole (14), but decreased perfusion of the in-
volved lung should not be considered a contraindica-
tion for resection (14,19). In our series of patients lo-
bectomy has been possible in perfusion of 32% and 
bilobectomy in perfusion of 25%. 
Ali M.K. et al. (1) describes the phenomenon of 
early disproportional loss of pulmonary function af-
ter lobectomy, which is a serious consequence for the 
patients with borderline pulmonary reserves. Pre-
dicting of this transient decline of pulmonary func-
tion is important for increase of survival and reduc-
tion of incidents of respiratory impairment of these 
patients. Chenuel B. et al. (2) study the effect of load-
ing with lung perfusion scintigraphy of lung carci-
noma patients to predict the post-operative pulmo-
nary function and establish that scintigraphy in rest 
gives clear picture of lung functional capacity before 
resection. 
Conventional functional tests of the lungs have 
low importance for predicting the output from the 
operation in individual cases (8). The accuracy of the 
quantitative perfusion scintigraphy for predicting the 
pulmonary function after operation is better than the 
simple calculation (7). Perfusion scintigraphy is sim-
ple and probably the best method for predicting the 
pulmonary function (19). Each lobectomy has spe-
cific magnitude of ventilation loss and perfusion or 
forced vital capacity in the operated lung. Left up-
per lobectomy is related with higher functional loss-
es than right upper lobectomy or left lower lobectomy 
(9). Predicting by scintigraphy of residual functional 
after lobectomy has greater extent of inaccuracy than 
in pulmonectomy (5). When lobectomy is combined 
with inductive chemo- or radiotherapy it is connect-
ed to additional pulmonary functional loss in the late 
post-operative phase (3). Ventilation-perfusion scans 
can predict postoperative pulmonary function and 
help evaluate the risk of surgery for lung cancer pa-
tients with borderline pulmonary functions (20).
The assessment of regional perfusion is better 
prognostic indicator than regional ventilation. There 
is better co-relation between perfusion and surviv-
al than between ventilation and survival. Patients 
with small circulatory changes have 5 year survival 
of 31,7% (18). In our series of examination median 
survival time of the patients with small perfusion de-
fects of the affected lung (>49%) is 64 months (5,3 
years).
When comparing the median survival 
according to the stage in our series versus data from 
Goldstraw P. et al. (4) the data for stage I and II are 
corresponding – 112 months, but in stage III A and 
stage IIIB median survival length of our patients 
is higher. There is a probability that assessment of 
pulmonary function in the late stages by perfusion 
indices to have prognostic value for indicating better 
survival which is observed in our series of operated 
patients. The emerging from the comparison of data 
question would be investigated in further analysis. 
Carcinomatous lung almost always has de-
creased perfusion. Only about 6% of the patients 
with bronchogenic carcinoma has perfusion of more 
than 50% from the whole lung perfusion with carci-
noma. In this small number of patients pulmonec-
tomy would represent high risk and they should be 
identified before resection (10). In our patients 8 pre-
sented with perfusion over 50% in the affected lung 
from carcinoma, 7 with localization in the right lung 
and 1 localized in the left lung.
CoNCLUSIoN
Lung perfusion scintigraphy is a valuable 
method for pre-operative diagnostics of lung 
carcinoma to determine the size of perfusion 
impairments in the affected lung and functional 
operability. Lobectomy is possible when perfusion 
of the affected lung is over 41%, but lower perfusion 
is not a clear contraindication for lobectomy. The 
extent of perfusion changes is proportional to 
survival. Patients with small perfusion changes have 
over 5 years median survival. In postoperative period 
perfusion scintigraphy shows the re-distribution 
of perfusion in the non-affected lung and in the 
residual part of the operated lung. The survival of the 
patients with lobectomy corresponds with clinical 
stage statistically significant. 
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